Latest News and Press Releases

60 Degrees and Tulane to study tafenoquine against Lyme and Bartonella bacteria, part of the “3Bs” common in tick-borne illness co-infections.

60 Degrees closes $5M public offering with up to $5M more from short-term warrants; funds support working capital and infectious disease R&D.

60 Degrees Pharma (SXTP) prices $5M public offering with potential $5M from warrant exercise; funds to support working capital and corporate purposes.

60 Degrees sets human babesiosis TAM for ARAKODA at $245M annually, $1.1B total through 2035; NDA planned for 2026 pending trial data.

60 Degrees launches 8-count ARAKODA® bottles, offering weekly malaria protection for short trips. Now available via major retail pharmacies.

Insurance claims show U.S. babesiosis incidence may be 10x CDC estimates; 60 Degrees links chronic fatigue and plans 2026 NDA for tafenoquine treatment.

60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.

60 Degrees Pharma will import KODATEF® from Australia to ensure U.S. tafenoquine supply, addressing rising ARAKODA® demand.

60 Degrees Pharmaceuticals announces IRB approval for Phase II study of tafenoquine for chronic babesiosis, with enrollment starting Q3 2025.

60 Degrees Pharma (Nasdaq: SXTP) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment.